Corvus Pharmaceuticals, Inc.

CRVS | Nasdaq | CIK: 0001626971 | SIC: 2834 Pharmaceutical Preparations | active
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapy treatments. Its pipeline includes soquelitinib (formerly CPI-818), ciforadenant, and mupadolimab. The company conducts clinical trials for these product candidates, leverages biomarker data to support clinical development, and has a collaboration with Angel Pharmaceuticals. Corvus has not yet commercialized any products.
oncologycancer-immunotherapy
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/CRVS
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
Soquelitinib (formerly CPI-818)platformClinical-stage cancer immunotherapy product candidate currently in ongoing and planned clinical trials.
CiforadenantplatformClinical-stage cancer immunotherapy product candidate currently in ongoing clinical trials.
MupadolimabplatformClinical-stage cancer immunotherapy product candidate currently in ongoing clinical trials.

Partnerships

PartnerTypeDescription
Angel PharmaceuticalsstrategicCollaboration with Angel Pharmaceuticals as part of Corvus's ongoing business development efforts.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/CRVS/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub